Search BTMD
biote Corp.
Nasdaq · CIK 1819253
Last close1.15
Daily change-0.01 (-0.86%)
10 Years gain-88.56%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BTMD · STANDARD
SIC 2833 · Medicinal Chemicals & Botanical Products · Fiscal year end 1231
Fundamental
50.2Momentum
22.8Acceleration
22.8Confidence
84.0Annual Revenue5
Quarterly Revenue19
Annual CFO5
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth2.0 / 25
Quality20.1 / 25
Capital Efficiency20.0 / 20
Balance Sheet8.2 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Share count reductionDiluted share count declined 22.5336%.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Operating margin compression · MEDIUMOperating margin compressed by 5.4359 percentage points.
Key Metrics
Revenue Growth TTM-6.72%OK
Revenue CAGR 3Y5.23%OK
Gross Marginn/aMISSING
Operating Margin10.05%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC100.51%OK
Incremental Operating Margin 3Y609.9%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-22.53%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $192.22M | n/a | $35.55M | $35.19M | $30.18M | n/a | 18.5% | 15.7% | n/a | 36.67M |
| 2025 FY Dec 31, 2024 | $197.19M | n/a | $31.61M | $45.24M | $38.81M | n/a | 16.03% | 19.68% | n/a | 34.27M |
| 2024 FY Dec 31, 2023 | $185.36M | n/a | $28.66M | $26.88M | $26.52M | n/a | 15.46% | 14.31% | n/a | 25.71M |
| 2023 FY Dec 31, 2022 | $164.96M | n/a | -$60.72M | -$9.16M | -$9.49M | n/a | -36.81% | -5.75% | -239.94% | 8.06M |
| 2022 FY Dec 31, 2021 | $139.40M | n/a | $34.56M | $33.72M | $32.27M | n/a | 24.79% | 23.15% | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $185.99M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-340364, 0001193125-25-272294 |
| Revenue Growth TTM | -6.72% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-340364, 0001193125-25-272294 |
| Revenue CAGR 3Y | 5.23% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-106099 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001193125-26-106099 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | -39.46% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001193125-26-340364, 0001193125-25-272294 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | 10.05% | Operating Income / Revenue | OK | 0001193125-26-340364, 0001193125-25-272294 |
| ROIC | 100.51% | NOPAT / Average Invested Capital | OK | 0001193125-26-340364, 0001193125-25-272294 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-340364 |
| Current Ratio | 1.43x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.09x | (Cash + Short-term Investments) / Total Debt | OK | 0001193125-26-340364 |
| Revenue per Diluted Share | $6.50 | Revenue / Diluted Shares | OK | 0001193125-26-340364, 0001193125-25-272294 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |